Core Insights - INVO Fertility, Inc. has received a U.S. patent for a modified version of its INVOcell device, extending intellectual property protection until 2040 [1][4] - The INVOcell device is the first FDA-cleared intravaginal culture system, allowing fertilization and early embryo development within a woman's body, providing a more natural alternative to traditional IVF [2][5] Group 1: Patent and Intellectual Property - The newly issued patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, marking a significant milestone for the company [1][4] - The patent covers a simplified design of the INVOcell device, which has been developed based on clinical feedback and real-world use [3] Group 2: Product and Market Position - INVOcell was initially granted FDA clearance in 2015 and received an update in 2023 to extend the recommended incubation period from three days to five days [3] - The INVOcell procedure is designed to provide a more connected and affordable experience for patients compared to traditional ART treatments, with the potential for comparable results at a lower cost [5]

Core Viewpoint - INVO Fertility, Inc. is positioned for growth with a strengthened fundamental position, focusing on operational progress, disciplined capital management, and a clear growth strategy [3][4][21]. Operational Progress - The company has three operational fertility clinics generating positive cash flow, marking a critical milestone in achieving profitability at the clinic level [5]. - INVO Fertility is nearing the acquisition of a fourth clinic in Indianapolis, which will diversify revenue and enhance earnings power [6]. Financial Performance - The combined pro forma annualized revenue run rate from all clinics is approximately $9 million, providing a strong baseline for growth [7]. - The company has simplified and strengthened its capital structure, with recent financing issued at a fixed price of $1.59, enhancing clarity and alignment for shareholders [16][17]. Growth Strategy - Organic growth is a key component of the strategy, focusing on increasing patient volumes and optimizing treatment pathways [8][9]. - Acquisitions are a cornerstone of growth, with a robust pipeline of potential targets under evaluation, emphasizing clinics with strong reputations and operational improvement opportunities [10][11][12]. Market Environment - Recent executive actions support federal access to IVF and fertility treatments, potentially increasing patient demand and utilization of fertility services [13]. - The company anticipates strong growth in 2026, driven by acquisitions and organic expansion, addressing the rising global infertility rates and limited access to affordable services [14][15]. Future Outlook - INVO Fertility is positioned for a higher-growth phase with a stabilized operational base and a strong balance sheet, aiming to build a scalable platform for sustained growth [19][21].

As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878-9505 (Addres ...

As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878- ...

Core Viewpoint - INVO Fertility Inc. has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants, resulting in expected gross proceeds of approximately $7.5 million [1][3]. Group 1: Warrant Inducement Agreement - The investor has agreed to a reduced exercise price of the December 2025 Warrants to $1.59, allowing the purchase of 4,733,728 shares of common stock [1]. - In exchange for the immediate exercise of existing warrants, the company will issue unregistered warrants to purchase an additional 9,467,456 shares at the same exercise price of $1.59, subject to shareholder approval [3]. - The closing of the warrant exercise transactions is anticipated to occur on or about January 30, 2026, pending customary closing conditions [4]. Group 2: Financial Advisory and Compliance - Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction [2]. - The New Warrants are being offered in a private placement under an exemption from the registration requirements of the Securities Act of 1933, and have not been registered under the Act [5]. Group 3: Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) care, operating fertility clinics and offering the INVOcell medical device [7]. - The company has two operational INVO Centers in the U.S. and one IVF clinic, and continues to sell and distribute INVOcell to third-party clinics [7]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, providing a more intimate and affordable experience compared to traditional IVF [7].

Summary of INVO Fertility FY Conference Call Company Overview - **Company Name**: INVO Fertility - **Ticker Symbol**: IVF (NasdaqCM) - **Industry**: Fertility healthcare - **Business Model**: Operates clinics providing patient care and develops medical devices for fertility treatment, specifically the INVOcell device [3][4] Market Insights - **Market Size**: The U.S. fertility market is estimated to be between $5 billion and $7 billion annually, spread across approximately 460 clinics [4] - **Growth Trends**: The market is experiencing steady growth, but high treatment costs remain a barrier for many potential patients, leading to a significant number of untreated cases each year [4][5] - **Government Initiatives**: Recent policy updates aim to improve affordability, which is expected to increase demand for fertility services [7] Company Growth Strategy Organic Growth - **Key Drivers**: - Increasing outreach programs to boost patient flow - Adding new services and resources to existing clinics - Expanding clinic operations to handle more patient volume [9][10] Acquisition Strategy - **Acquisition Focus**: Acquisitions are a key strategy for near and intermediate-term growth, with a robust pipeline of potential opportunities [11][12] - **Recent Acquisitions**: The company is nearing completion of an acquisition in Indianapolis and has previously acquired a clinic in 2023 [11][12] - **Long-term Growth**: Building new clinics is seen as a significant long-term growth opportunity, with successful examples in Birmingham, Alabama, and Atlanta, Georgia [12] Recent Performance and Initiatives - **Patient Flow Initiatives**: Increased social media presence and targeted advertising are being implemented to attract more patients [15] - **Telehealth Expansion**: Telehealth capabilities have been introduced to improve patient convenience and operational efficiency [17] - **Device Sales Growth**: There has been year-over-year growth in device sales, with renewed focus on training and support for the INVOcell device [19][20] Challenges and Opportunities - **Acquisition Challenges**: While there are many acquisition opportunities, the complexity of closing deals presents a challenge [23] - **Team Expertise**: The company believes it has the necessary expertise to navigate these challenges and meet acquisition objectives for the year [24] Investor Takeaways - **Outlook for 2026**: The company is optimistic about growth prospects, combining organic growth efforts with acquisitions to enhance overall performance [26] - **Positioning**: The management team feels that the company is well-positioned to achieve significant progress and success in 2026 [26]

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

Core Viewpoint - INVO Fertility, Inc. has announced a realignment of its executive leadership team to better support its growth strategy focused on the establishment and acquisition of fertility clinics and related businesses [1][3]. Leadership Changes - Terah Krigsvold has been appointed as the new Chief Financial Officer (CFO), replacing Andrea Goren, who will now serve as Chief Business Officer and CEO of INVO Centers LLC, a subsidiary focused on fertility clinics [2][3]. - The leadership changes are intended to enhance the company's ability to execute its growth plan and achieve profitability [3]. Company Strategy - INVO Fertility is dedicated to expanding access to assisted reproductive technology (ART) and focuses on building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [4]. - The company currently operates two INVO Centers and one IVF clinic in the United States and is involved in the sale and distribution of the INVOcell device to third-party clinics [4]. Product Offering - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more intimate and affordable experience compared to traditional ART treatments [4]. - The IVC procedure enabled by INVOcell is believed to deliver comparable results to traditional IVF at a significantly lower cost and is more effective than intrauterine insemination [4].

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...